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Abstract
Sepsis remains a significant cause of neonatal morbidity and mortality in China. A better understanding of neonatal sepsis in China
as compared with other industrialized and non-industrialized countries may help optimize neonatal health care both regionally and
globally. Literature cited in this review was retrieved from PubMed using the keywords “neonatal sepsis,” “early-onset (EOS)” and
“late-onset (LOS)” in English, with the focus set on population-based studies. This review provides an updated summary regarding
the epidemiology, pathogen profile, infectious work-up, and empirical treatment of neonatal sepsis within and beyond China. The
incidence of neonatal EOS and the proportion of Group B Streptococcus (GBS) within pathogens causing EOS in China seem to
differ from those in developed countries, possibly due to different population characteristics and intrapartum/postnatal health care
strategies. Whether to adopt GBS screening and intrapartum antibiotic prophylaxis in China remains highly debatable. The
pathogen profile of LOS in China was shown to be similar to other countries. However, viruses as potential pathogens of neonatal
LOS have been underappreciated. Growing antimicrobial resistance in China reflects limitations in adapting antibiotic regimen to
local microbial profile and timely cessation of treatment in non-proven bacterial infections. This review stresses that the local
epidemiology of neonatal sepsis should be closely monitored in each institution. A prompt and adequate infectious work-up is
critically important in diagnosing neonatal sepsis. Adequate and appropriate antibiotic strategies must be overemphasized to
prevent the emergence of multi-resistant bacteria in China.
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Introduction
Neonatal sepsis is a cause of significant morbidity and
mortality. Based on population-level studies during the last
two decades, the global estimate of the incidence of
neonatal sepsis was 2202 (95% confidence interval [CI]
1099–4360) per 100,000 live births (LBs), with mortality
between 11% and 19%.[1,2] In China, birth population-
based surveys from one region that have approximated
national average levels estimated the incidence of neonatal
sepsis to be 25.6 per 1000 LBs.[3] Between 1996 and 2015,
the cause-specific mortality of neonatal sepsis in China
decreased from 0.4 to 0.1 per 1000 LBs, which was
significantly lower than the global estimate of 2.8 per 1000
LBs in 2015.[4] Notably, great inequity exists in mortality
rate of neonatal sepsis across regions in China.[4]
Clinical signs of neonatal sepsis range from sub-clinical
infection to severe manifestations of focal or systemic
disease.[5] The pathogens responsible for sepsis might be
acquired through in utero infection,[6] maternal microbiota
during delivery, or postnatal hospital or community
environment.[7] The timing of the exposure, inoculum
size, immune status of the infant, and virulence of the
causativemicro-organismmay greatly influence the clinical
manifestations of neonatal sepsis. Based on different
definitions across regions, early-onset sepsis (EOS) occurs
within the first 3 to 6 days of life, whereas late-onset sepsis
(LOS) occurs after 4 to 7 days within the first 1 to 3months
of life.[5] Apart from the onset of time, there are marked
differences in terms of pathogen profile and antimicrobial
susceptibility among EOS, community-acquired LOS, and
hospital-acquired LOS.[7,8] In light of the above, great
challenges exist to manage and reduce neonatal sepsis.
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China is one of the most populous countries in the world
with some regions closely approaching industrialized
countries in terms of socioeconomic development and
health care, while some relatively lagging behind. The
second-child policy since 2015 may further complicate the
clinical picture of neonatal sepsis. Therefore, this review
will provide an updated summary regarding important
aspects of neonatal sepsis, such as epidemiology, pathogen
profile, infectious work-up, and empirical treatment, both
within and beyond China, in the hope of optimizing
neonatal health care both regionally and globally.
Early-Onset Neonatal Sepsis
Incidences and pathogen profiles
Industrialized countries
In developed countries like USA, although the overall
incidence of EOS has remained relatively stable at around
0.8 casesper1000LBsover the last twodecades,[9] there have
been marked changes in the pathogen-specific incidence of
EOS. Group B Streptococcus (GBS) and Escherichia coli are
predominant pathogens of neonatal EOS, accounting for
36% and 25%of EOS cases identified in four US States from
2005 to 2014.[9] Particularly, in the National Institute of
Child Health and Human Development birth cohort of very
low birth weight (VLBW) infants, there was a marked
reduction in EOS caused by GBS (from 5.9 to 2.08 per 1000
LBs, P< 0.001), but an increase in E. coli sepsis (from 3.2 to
5.09 per 1000 LBs, P= 0.004) between 1991–1993 and
2006–2009.[10,11] In contrast, the incidence of GBS EOS
plateaued or even slightly increased in some other developed
countries [Table 1].[12,13] It has been speculated that
different population structure, emergence of newGBS clones,
increased recognition of EOS symptoms, and modified
criteria fordiagnosingneonatal sepsismighthave contributed
to higher incidence ofGBSEOSover time in some regions.[13]
Non-industrialized countries
In contrast, the incidence of neonatal GBS EOS is less clear
in developing countries, mainly due to limitations in
Table 1: Population-based studies reporting on temporal changes in the incidence of neonatal early-onset sepsis.
Network Birth year
Population
of cohort
No. of
neonates
Onset of
EOS (days)
Incidence of EOS
(per 1000 LBs)
Case fatality
n/N, %
USA
NICHD[10] 1991–1993 VLBW 7606 3 All pathogens: 19.3
GBS: 5.9
E. coli: 3.2
NA
1998–2000 VLBW 5447 3 All pathogens: 15.4
GBS: 1.7
E. coli: 6.8
31/84, 37%
NICHD[11] 2006–2009 All LBs 396,586 3 All pathogens: 0.98
GBS: 0.41
E. coli: 0.28
61/389, 16%
15/160, 9%
35/107, 33%
VLBW 12,956 3 All pathogens: 10.96
GBS: 2.08
E. coli: 5.09
NA
UK
CoSurv[12] 2000–2001 All LBs 794,037 6 GBS: 0.48 38/377, 10.6%
NeonIN[13] 2006–2008 All LBs 130,763 2 All pathogens: 0.9
GBS: 0.5
E. coli: 0.2
NA
BPSU[20] 2014–2015 All LBs 914,132 6 GBS: 0.57 27/517, 5.2%
VLBWs 7569 6 GBS: 2.24
The Netherlands
AMC-RVIM[19] 1987–1999 All LBs NA <7 GBS: 0.11 NA
2000–2011 All LBs NA <7 GBS: 0.19
Asia
Five NICUs[15]
in China, Kuwait,
Malaysia, Thailand
2005 All LBs 35,294 2 All pathogens: 0.72
GBS: 0.51
GNB: 0.15
6/47, 12.8%
4/18, 22%
2/17, 12.5%
Three NICUs[16]
in China, Malaysia,
Thailand
2006–2009 All LBs 76,141 <3 All pathogens: 0.62
GBS 0.24
GNB: 0.11
13/181, 7.2%
China[17] 2015–2018 All LBs < 34 weeks 19,084 <3 All pathogens: 9.7 42/186, 22.6%
EOS: Early-onset sepsis; LBs: Live births; NICHD: National Institute of Child Health and Human Development; BPSU: British Paediatric Surveillance
Unit; AMC-RVIM: Netherlands Reference Laboratory for Bacterial Meningitis of the Amsterdam Medical Center and the National Institute of Public
Health and the Environment; NICU:Neonatal intensive care unit; VLBW: Very low birth weight; NA: Not available; GBS: Group B Streptococcus; GNB:
Gram-negative bacilli.
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detection methodology as well as difficulties in defining
population denominator.[14] Although not based on
nationwide surveillance system, two consecutive prospec-
tive multi-center studies in Asia have shed some light on the
trend of neonatal EOS in this region, showing a steady
decline in overall as well as pathogen-specific incidence of
EOS from 2005 to 2009 [Table 1].[15,16] Meanwhile, the
overall case fatality of EOS decreased by nearly 40%
[Table 1].[15,16] Moreover, EOS in developing countries
may have different pathogen profiles. Based on a recent
multicenter study including preterm infants <34 weeks’
gestation admitted to 25 tertiary neonatal units in China
(2015–2018), the incidence of EOS was 11.7 cases per
1000 admissions (321/27,532) or 9.7 cases per 1000 LBs if
only inborn infants in 18 perinatal centers were considered
(186/19,084).[17] The leading pathogen was Gram-nega-
tive bacteria (GNB) like E. coli (20.3%), followed by
coagulase-negative staphylococci (CoNS) (16.5%), where-
as EOS caused by GBS was relatively rare (2.5%).[17] The
case fatality rate of EOS in China was 19% (61/321).[17]
Intrapartum antibiotic prophylaxis (IAP) for EOS
The US
As the primary risk factor for neonatal GBS EOS is
maternal colonization of the genitourinary and gastroin-
testinal tracts, the American College of Obstetricians and
Gynecologists (ACOG) recommends universal maternal
screening by vaginal-rectal culture between 36 and 38
weeks of gestation to effectively prevent GBS EOS
[Supplementary Figure 1A–1C, http://links.lww.com/
CM9/A244, http://links.lww.com/CM9/A245, http://links.
lww.com/CM9/A246].[18] Approximately 50% of women
who are colonized with GBS will transmit the bacteria to
their newborns.[18] Vertical transmission usually occurs
during labor or after preterm premature rupture of
membranes.[6] In the absence of IAP, 1% to 2% of these
newborns will develop GBS EOS.[18] All women whose
vaginal-rectal cultures are positive for GBS should receive
appropriate IAP, mostly penicillin or amoxicillin, unless a
pre-labor caesarian section is performed in the setting of
intact membranes.[18] Although a shorter duration of
recommended intrapartum antibiotics less than 4 h may
not be as effective as that of more than 4 h, 2 h of antibiotic
exposure has been shown to reduce GBS vaginal colony
counts and decrease the frequency of a clinical neonatal
sepsis diagnosis. Obstetrical interventions, whenever
necessary, should not be delayed in order to provide the
4-h antibiotic administration before birth.[18]
Europe
In contrast to universal maternal screening, risk-based
stratification has been adopted in other industrialized
countries.[12,13,19] Based on a prospective national surveil-
lance of invasive GBS in infants younger than 90 days from
2014 to 2015 in the UK and Ireland, the incidence of all
GBS infection was 0.94 (95%CI 0.88–1.00) per 1000 LBs,
with GBS EOS being 0.57 (95% CI 0.52–0.62) per 1000
LBs.[20] The case fatality rate of GBS EOSwas 5.2%, lower
than that in the US [Table 1].[10,11,20] Notably, both the
incidence and case fatality rate were about five-fold higher
in VLBW infants than in those with a BW >1500 g. In the
Netherlands, despite IAP guidelines to prevent GBS EOS
on the basis of culture-based screening at 35 to 37 week’s
gestation, the incidence of GBS EOS increased slightly over
the last two decades, demonstrating a similar secular trend
as in the UK [Table 1].[19] In the UK, five serotypes (Ia, Ib,
II, III, V) accounted for 377 (94%) of all isolates GBS
strains, with the predominant serotypes being III (60%)
and Ia (17%).[20] A particular concern is the large number
of isolates identified as sequence type (ST)17, a clone
associated with a high risk of invasive neonatal sepsis and
meningitis.[21] Thus, much hope lies on a vaccine against
GBS which is still under development.[22]
China
Currently, no standard guidelines exist for maternal GBS
screening and neonatal GBS disease prevention in China.
While some hospitals perform IAP following a risk-based
strategy, others apply universal screening recommended by
ACOG. A recent systematic review of published data from
Chinese literature revealed that the maternal GBS
colonization rate in the mainland of China may range
from 5.7% to 14.5% among institutions.[23] Based on so
far the largest population-based surveillance study for GBS
disease burden from 18 urban tertiary hospitals across 16
Chinese provinces (2015–2017), the overall incidence of
invasive GBS disease in infants 3 months of life was
estimated to be 0.31 (95% CI 0.27–0.36) cases per 1000
LBs, ranging from 0 to 76 cases per 1000 LBs across
participating hospitals.[24] The incidence of early- and late-
onset GBS disease was 0.18 (95% CI 0.15–0.22) and 0.13
(95% 0.11–0.16) per 1000 LBs, respectively.[24] The
majority (76.6%) of invasive GBS disease occurred in term
infants, and only 13.2% of GBS-case mothers received
GBS screening during pregnancy.[24] Similar to the UK, five
serotypes (Ia, Ib, II, III, and V) accounted for the majority
of GBS invasive cases in the mainland of China, and
isolated GBS strains were most commonly III serotype and
ST 17.[23,24] Due to population characteristics and
sociocultural background, the actual rate of maternal
GBS colonization and neonatal GBS diseases in China may
differ greatly from those reported in industrialized
countries, and are probably much lower based on current
knowledge. Unresolved issues remain as to whether GBS
screening and prevention protocols should be incorporated
in China, and if so, what kind of strategies. As such,
immunizing pregnant women against GBS, despite being
an emerging approach to protect neonates from GBS
disease in some countries, could not yet be introduced in
China.
So far, chorioamnionitis as a significant risk factor of
neonatal EOS has not been fully appreciated in China. It
has been suggested that pathological and microbiological
examination of the placenta should be routinely per-
formed, especially in preterm deliveries, in order to better
assess EOS and combined perinatal co-morbidities.[25]
Notably, the predominance of nosocomial and opportu-
nistic pathogens (eg, GNB and CoNS) among neonatal
EOS cases in China raised the concern of possible
unhygienic practices or inappropriate perinatal exposure
to antibiotics favoring intestinal translocation of GNB.[17]
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Late-Onset Neonatal Sepsis
Maternal post-partum transmission of GBS is
underestimated
LOS still accounts for about one-third of neonatal GBS
sepsis, and the case fatality rate of GBS LOS was higher
than that of GBS EOS (7.7% vs. 5.2%).[20] Mother-to-
infant transmission may constitute an important source of
GBS LOS. A longitudinal study was carried out in 160
mother-baby pairs from Italy to assess postnatal coloniza-
tion with GBS and the impact of IAP.[26] Specimens from
the rectum, vagina, and milk of mothers were collected
from the time of delivery to 8 weeks post-partum. Women
were grouped into culture-positive carriers (n= 83),
culture-negative carriers (n= 26), and non-carriers
(n= 51) at discharge from hospital. A total of 35 (22%)
neonates were colonized by GBS from at least one body
site, and the majority of them (30/35) were born to culture-
positive carriers. Infants of culture-positive carriers
exposed to IAP were less likely to be colonized (15/57
vs. 15/26, P= 0.01), or heavily colonized (7/57 vs. 1/26,
P= 0.04). However, neonates exposed to IAP and dis-
charged GBS-free from hospital often became subsequently
colonized (12/57 vs. 1/26, P= 0.09), and six out of 83
culture-positive carrier mothers showed positive milk
cultures with heavy colonization of GBS in their babies.
Molecular typing analysis confirmed identical GBS strains
in all mother-baby pairs. These data call the attention of
physicians to maternal transmission after delivery as an
underestimated source of neonatal LOS.
GNB are associated with severe neonatal LOS
Despite being less common than Gram-positive bacteria to
cause neonatal LOS, GNB are associated with more severe
clinical manifestations such as meningitis, and have a
higher mortality, especially in VLBW infants.[27]E. coli is
the most common cause of bacterial meningitis in preterm
infants and the second most common after GBS in term
neonates in the UK.[28] In France, the average number of
LBs each year was around 800,000 between 2001 and
2013, of whom 6.6% were born preterm.[29] In 2001, the
Pediatric Infectious Group of the French Pediatric Society
(GPIP/ACTIV) established an active bacterial pediatric
meningitis surveillance network including 233 pediatric
wards and 168 microbiology laboratories. From 2001 to
2013, 325 infants were prospectively diagnosed with
E. coli meningitis, which was seven-fold more frequent in
preterm than in term infants.[30] The median age at
diagnosis was 14 days, with two peaks of infection onset at
0 to 3 days of age (EOS in mostly preterm neonates), and
11 to 15 days of age (LOS in mostly term infants). Severe
clinical manifestation was reported in 51.9% of patients,
and 9.2% died. Death was associated with very preterm
birth (odds ratio [OR]: 7.3, 95% CI 2.7–20.9; P< 0.001),
cerebrospinal fluid (CSF) to blood glucose ratio<0.1 (OR:
15.3, 95% CI 1.8–128.3; P= 0.012), uncommon strains
like O7 serogroup (P= 0.034), and PapGII adhesin (OR:
2.3, 95% CI 1.2–4.5; P= 0.015). Translocation of GNB
into the systemic circulation via an interrupted gastroin-
testinal barrier has been speculated to be a key mechanism
of GNB LOS.[27,31]
Pathogen profiles of community- and hospital-acquired
neonatal LOS
An emerging body of evidence has demonstrated complete-
ly different microbiological findings between various types
of sepsis. This is of critical importance to guide empirical
antibiotic therapy strategy, which should not only be
adapted to the timing (early vs. late), but also to
circumstances (hospital- vs. community-acquired).
Industrialized countries
To assess the epidemiology and types of neonatal sepsis, all
newborn infants with blood culture-proven sepsis admit-
ted to neonatal intensive care units (NICUs) in Switzerland
between 2011 and 2015 were included.[7] Infants with
LOS were classified as community- or hospital-acquired
LOS if onset of infection was 48 or >48 h following
admission. In 429 infants there were 444 episodes of blood
culture-proven sepsis, with 20%, 62%, and 18% being
EOS, hospital-acquired LOS, and community-acquired
LOS, respectively. Correspondingly, the estimated inci-
dence was 0.28, 0.86, and 0.28 per 1000 LBs, and case
fatality 18%, 12%, and 0%, respectively. Major patho-
gens were GBS, other Gram-positive bacteria, and E. coli
for EOS; GBS and E. coli for community-acquired LOS. In
contrast, CoNS, Staphylococcus aureus, and other GNB
were mostly isolated in hospital-acquired LOS [Supple-
mentary Figure 2A, http://links.lww.com/CM9/A247 and
2B, http://links.lww.com/CM9/A248].[7]
Non-industrialized countries
The burden of neonatal infections in developing countries is
highly variable, maybe because of the lack of vital registries
and surveillance systems.[32] Information about communi-
ty-acquired bacteremia in South Asia and Southeast Asia
was approached through a review of 17 eligible studies
enrolling 40,644 patients.[33] Pathogenic organisms were
isolated in 1722 (7%) of 26,258 children. Salmonella
enterica serotype Typhi was the most common bacterial
pathogen. Other commonly isolated organisms in children
were Streptococcus pneumoniae andHaemophilus influen-
zae, probably reflecting the lack of large-sale vaccination.
Severe bacterial infections are a leading cause of death
among neonates in low-income countries with poor hygiene
and frequent exposure to antibiotics without documenta-
tion of bacterial infection, resulting in the emergence and
spread of multi-resistant bacteria.[34] With advancing
pediatric healthcare, the use of central venous catheters
(CVC) has become a fundamental part of neonatal and
pediatric intensive care.[35] Maximal sterile barrier precau-
tions have been shown to independently contribute to
decreased CVC-associated bloodstream infection in VLBW
infants.[36] Currently, there is a lack of population-based
data on the pathogen profile of neonatal LOS in China.
Gram-positive bacteria, mainly CoNS and S. aureus, were
indicated as being responsible for the majority of neonatal
LOS, whileE. coli andKlebsiella spp. may account formost
GNB LOS.[16,37-41]. Most hospital-acquired LOS occurred
in very preterm infants whowere very likely to receive some
kindof ventilatory support andparenteral nutrition through
a CVC.[42]
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Neonatal Viral Sepsis
The incidence of overall viral sepsis
Viruses are common but largely underappreciated patho-
gens of neonatal sepsis. In a population-based pregnancy
surveillance at five sites in Bangladesh, India, and Pakistan
from 2011 to 2014, babies with illnesses meeting the
World Health Organization definition of possible serious
bacterial infections (pSBI) were referred to study physi-
cians for culture and molecular assays of blood and
respiratory samples.[8] Among 63,114 babies, 6022 pSBI
episodes were identified (95.4 per 1000 LBs), with causes
specified in 28% of episodes (16% bacterial and 12%
viral). The mean incidence of bacterial and viral infections
was 13.2 (95% credible interval 11.2–15.6) and 10.1
(95% credible interval 9.4–11.6) per 1000 LBs, respec-
tively. The leading viral pathogen was respiratory syncytial
virus (5.4 per 1000 LBs). This study was among the first to
provide valuable population-based data on neonatal viral
sepsis with universal detection of pathogen species. So far,
species-specific data on neonatal viral sepsis are limited.
Herpes simplex virus (HSV)
HSV may cause potentially devastating infection in
neonates. However, large-scale assessment of its frequency
in potentially infected infants has not been performed,
apart from one retrospective cross-sectional study in 23
North American pediatric emergency departments enroll-
ing infants 60 days old with CSF samples for HSV
polymerase chain reaction (PCR) or culture.[43] Of 26,533
eligible encounters, 112 infants had HSV identified
(0.4%), corresponding to 1.2% of all infants tested for
HSV. Among them, 90 (80.4%) occurred in weeks 1 to 4,
with the median age of HSV-infected infants being 14 days
(interquartile range 9–24 days). Notably, 68 of 112 test-
positive infants had central nervous system (CNS) or
disseminated HSV disease. The proportion of infants
subjected to an HSV test (35%, range 14%–72%) and to
whom acyclovir was administered (23%, range 4%–53%)
varied widely across centers. Thus, both pediatric
emergency physicians and neonatologists should keep in
mind this rare but deadly cause of neonatal sepsis, which
requires urgent acyclovir administration. A careful review
of the maternal history and close communication with
obstetricians are critical for a timely diagnosis and
treatment of neonatal HSV disease.
Enteroviruses
Enteroviruses have been increasingly recognized to be
causes of meningitis, sepsis-like disease, and fever without
source in neonates and older children. A prospective
multicenter study performed at 35 French pediatric and
emergency departments has shown that positive blood
PCR results for enterovirus was common.[44] Between
2015 and 2016, a total of 71 newborns were subjected to
enterovirus testing, the detection of enterovirus was more
frequent in blood than in CSF (70/71 vs. 62/71, P= 0.011).
As such, PCR for enterovirus should be part of the sepsis
workup in neonatal sepsis, and empiric antibiotic therapy
should be promptly discontinued in confirmed cases of
viral infection. So far, there is a lack of population-based
data on neonatal infection due to enterovirus in China. In a
hospital-based prospective study in a level-3 NICU in East
China, enterovirus infection among febrile neonates with
an admission temperature >38°C was diagnosed by PCR
testing of stool and/or CSF samples.[45] One-hundred
thirty one (39.2%) of 334 febrile neonates had PCR-
confirmed enterovirus infection, with PCR results being
positive in 130 (99.2%) of stool and in 58 (44.3%) of CSF
samples, respectively. Among 131 infected neonates,
mostly term infants in their 2 to 3 postnatal weeks, 69
(52.7%) had diarrhoea, 48 (36.6%) respiratory symp-
toms, 22 (16.8%) poor feeding, 34 (26.0%) rash, and 18
(13.7%) lower platelet counts <150 109/L.[45] These
data indicate that enterovirus infection may be common in
febrile neonates and stool samples should be included in
diagnostic work-up. Although all infected patients received
supportive treatment with none developing fulminant
disease course, the long-term outcome of neonates infected
with enterovirus may be worrying. Another case series of
12 Chinese neonates with a GA of 35 to 39 weeks showed
that enterovirus can cause severe encephalitis associated
with white matter damage in the neonatal period, and the
severity of the imaging abnormalities might correlate with
later neurodevelopmental outcome.[46]
Infectious Work-up of Neonatal Sepsis
Initial signs and symptoms of neonatal sepsis are oftenmild
and not specific. Infected infants are likely to appear
generally ill, without fever or system-related symptoms.
However, the disease course may also be fulminant with
development of septic shock, respiratory distress, neuro-
logical dysfunction, and even death. As such, a prompt and
adequate infectious work-up is essential for timely
diagnosis of neonatal sepsis and the prevention of adverse
outcomes.
Culture-dependent and independent tests
Sufficient amount (1–2mL) of blood should be taken to
optimize the yield of blood culture,[47] besides the volume
needed for a full blood cell count, venous pH, and lactate,
and other parameters to assess the disease status [Table 2].
Urine sample obtained via aseptic bladder catheterization
and CSF via lumbar puncture (LP) should be considered in
a respiratory- and hemodynamically-stable infant.[48-50] A
positive bacterial culture after 24 to 36 h confirm the type
of bacterial pathogen, and allows antimicrobial suscepti-
bility testing.[42] Biological markers, such as procalcitonin
(PCT), C-reactive protein (CRP), white blood cell, and
absolute neutrophil count (ANC), are not specific of
bacterial infection. However, the Lab-score based on PCT
levels (<0.5, ≥0.5, and ≥2 ng/mL), CRP levels (<40, 40–
99, and ≥100 mg/L), and urine dipstick (negative or
positive) has been shown to be highly predictive of a
urinary tract infection (UTI).[51] Nonetheless, UTI should
be defined by bacterial counts of uropathogen (mostly
E. coli), with the minimum concentration ranging between
105 and 106 colony-forming units/mL.[52] Recently, two
prediction rules to identify young febrile infants at risk of
SBI in the pediatric emergency department have been
validated. The “Step-by-Step” approach developed in
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Europe assesses abnormal clinical appearance at first,
followed by young age (<3 weeks), significant leukocy-
turia and bacteruria confirmed by high-power field
microscope, PCT >0.5 ng/mL, CRP >20 mg/L, or ANC
>10,000/mm3 to define low-risk and high-risk of SBI.[53]
The prediction rule of the PECARN group in USA
identifies febrile infants 60 days or younger at low risk
of SBI using the urinalysis, ANC, and PCT levels.[54]
Particularities of LP
LP is mandated in young febrile infants if sepsis is highly
suspected and the patient’s condition allows.[53-55] The
previously recommended practice of performing brain
imaging before a LP has been shown to significantly delay
antibiotic treatment and increase the likelihood of a poor
neurologic outcome, both in adults and children with
proven bacterial meningitis.[56,57] As a traumatic LP can
complicate the interpretation of CSF, it is helpful to
evaluate the mean spinal canal depth (MSCD) using either
the following ruleMSCD (mm) = 0.4weight (kg) + 20 or
direct ultrasound imaging.[58] Direct examination of CSF
sample under microscope is mandatory to determine the
bacterial type and number per high-power field, providing
valuable guidance for empirical antibiotic therapy. The
presence of Gram-positive cocci in long chains under
microscope may suggest GBS meningitis, and Gram-
negative bacilli meningitis caused by E. coli or even
extended-spectrum beta-lactamase (ESBL) Enterobacter-
iaceae, depending on microbial surveillance results at the
local institutions. In a multicenter study in Asia which
included 453 documented episodes of neonatal sepsis, the
most common pathogens for neonatal meningitis were
Klebsiella spp. (27/76), followed by CoNS (11/76) and
E. coli (10/76), with GBS identified only in one case.[15]
One recent province-level multicenter study in South China
including 838 cases of neonatal meningitis from 12
hospitals (2011–2016) showed that the first three causes
were GBS (88/249), E. coli (55/249), and CoNS (32/
249).[59]
Empirical Treatment of Neonatal Sepsis
Timing and regimen of antibiotics
Empirical antibiotic treatment should be initiated as soon
as neonatal sepsis is suspected, in fear of negative outcomes
associated with missed septic cases. As streptococci are
often sensitive to penicillin/ampicillin and about 50%
of E. coli, noticeably K1, are resistant to ampicillin/
amoxicillin, most recommendations of treating neonatal
EOS are now to combine amoxicillin/ampicillin with
gentamicin.[5,60] If culture confirms GBS, amoxicillin/
ampicillin is recommended, and gentamicin should be
discontinued after 48 h to prevent cumulative nephro- and
oto-toxicity.[61,62] In case of ampicillin-resistant E. coli
infection, a third-generation cephalosporin like cefotaxime
should be used (100mg/kg per day), and at a higher dosage
(200mg/kg per day) when meningitis is suspected. In case
of hospital-acquired LOS which is often caused by CoNS
like Staphylococcus epidermidis,[42] vancomycin by intra-
venous injection (or continuous infusion through a CVC if
it is infected) is recommended at first,[63,64] as many of
CoNS are indeed methicillin-resistant. When culture
results are positive for GNB, aminoglycoside is preferred
given its narrow spectrum and reduced risk of resistance.[5]
However, escalation to third-generation cephalosporin
and even carbapenem should be considered, depending on
local epidemiology, clinical presentation especially with
CNS involvement, and whether there is evidence of ESBL
Enterobacteriaceae.[5] As community-acquired LOS is
Table 2: Neonatal sepsis workup.
Parameter Test
Optimal conditions for specimen
collection Value in diagnosing neonatal sepsis
Infectious markers
Blood Culture 1–2 mL of blood Standard for bacteremia
Urine Culture Bladder catheterization Gold standard for UTI
CSF Culture Non-traumatic lumbar puncture Standard for meningitis
Nasopharyngeal PCR Winter epidemics, contact with a
sick case; Nasal aspirates for
RSV, nasal swab for influenza
virus
Discuss plausibility and PCR
positivity: possible respiratory
tract infection
Biological markers
pH, ABG, lactate Blood Arterial or venous sampling Lactate >2 mol/L (indicate
shock)
ANC Blood count Take into account the potential
normal range for postnatal age
Neutropenia <1500/mm3
(Not specific of bacterial
infection)
Platelets Blood count No clotting sampling Thrombocytopenia <50,000/mm3
PCT Blood 2–6 h after onset of infection >2 ng/mL (not specific)
CRP Blood 8–24 h after onset of infection >20 mg/L (not specific)
Sepsis scores[53,54] Multiple test 24 h after onset of sepsis Useful for low-risk SBI
CSF: Cerebrospinal fluid; ABG: Arterial blood gases; ANC: Absolute neutrophil count; PCT: Procalcitonin; CRP: C-reactive protein; PCR: Polymerase
chain reaction; RSV: Respiratory syncytial virus; UTI: Urinary tract infection; SBI: serious bacterial infection; IF: Immunofluorescence.
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often related to respiratory viral infections,[65] antibiotic
treatment must be rapidly discontinued when viral
infections is confirmed by multiplex PCR of nasopharyn-
geal aspirates.
The duration of antibiotic treatment
Recently, two statements regarding the management of
neonates born at <35 and >35 weeks’ gestation with
suspected or proven early-onset bacterial sepsis have been
released in the US.[66,67] Suspected EOS should always be
confirmed by cultures of blood, urine or CSF, and
antibiotic therapy should be discontinued if cultures are
sterile.[66,67] This rule also applies to the management of
LOS. Furthermore, non-specific biological markers (eg,
blood cell count, PCT, CRP) alone do not justify prolonged
use of antibiotics.[66,67] A fruitful dialogue should be
maintained between neonatologists and microbiologists
to optimize the duration of antibiotic treatment,
which relies often upon empirical rules: 7 to 10 days for
bacteremia, 14 days for Gram-positive meningitis, and 21
days for Gram-negative meningitis,[3,68] Given the general
trend to shorten antibiotic therapy and minimize the
selection of multi-resistant bacteria,[69] PCT as a highly
sensitive biomarker of sepsis has been investigated to guide
the cessation of antibiotic therapy.[70]
Overuse and misuse of antibiotics contribute to microbial
resistance
Both the inappropriate overuse of broad-spectrum anti-
biotics, such as third-generation cephalosporins and
carbapenem, and inadequacy of antibiotic stewardship
have led to the emergence of multi-resistant bacteria,
mostly ESBL Enterobacteriaceae, in neonatal sepsis in
China.[71] In a retrospective study reporting the temporal
trend of antimicrobial resistance over a period of 25 years
in the largest neonatal unit in Southwest China, a dramatic
six- and two-fold increase was found in the resistance rate
of ceftazidime and imipenem respectively, in Klebsiella
spp. isolated from neonates with sepsis.[38] A recent meta-
analysis of Chinese literature (2009–2014) on neonatal
sepsis revealed that more than 50% of E. coli and
Klebsiella spp. were resistant to third-generation cephalo-
sporin, and ampicillin resistance of E. coli was almost
80%,[37] similar to that in the US (85%).[11] Unsurpris-
ingly, the resistance rate of amikacin was relatively low
(around 10%–15%) in E. coli and Klebsiella spp.,[37]
probably due to the fact that aminoglycoside is not
routinely used to treat neonatal sepsis in China. Carba-
penem-resistance was found in 9% of E. coli and 6% of
Klebsiella spp., respectively.[37] Similar antibiotic suscepti-
bility results of GNB were corroborated by other
systematic reviews and web-based surveys.[72,73] As for
Gram-positive bacteria, although resistance to glycopep-
tide including vancomycin and linezolid seem to be rare in
China, methicillin resistance was reported for 60% to 70%
of Staphylococcus spp.[37,38,40]
Antimicrobial resistance in developing countries, such as
India[74] and Egypt,[75] is alarming. A very recent report
from a multinational, multicenter online database showed
that third-generation cephalosporin resistance rates among
Gram-negative isolates ranged from 26% to 84%, and
carbapenem resistance rates ranged from 0% to 81% in 12
low- and middle-income countries.[73] Glycopeptide resis-
tance rates among Gram-positive bacteria ranged from 0%
to 45%.[73] Staff to patient ratio and antibiotic availability
were considered to be key factors affecting antimicrobial
resistance rate in these settings.[73] The rising antibiotic
resistance very much complicates both the choice of initial
empirical antibiotic treatment and secondary antibiotic
strategy, as last-resource antibiotics are not readily
accessible in many settings.[76]
To minimize the selection of multi-resistant bacteria, there
is an urgent need to restrict antibiotic therapy to proven
neonatal bacterial infection and shorten antibiotic course.
Furthermore, surveillance and assessment of antibiotic
consumption has been demonstrated to positively influence
antibiotic stewardship strategy and reduce antibiotic
use.[77] Screening for GNB on neonatal body sites may
have a predictive value in neonatal LOS,[78] and
decolonization has been investigated as an approach to
prevent sepsis and the spread of multi-resistant GNB.[79]
However, the prognostic value of routine screening of
neonatal microbial colonization remains controversial,
due to a lack of high-quality evidence, especially in VLBW
infants.[31,78]
Supportive treatment of neonatal sepsis: uncertainties and
certainties?
Neonatal sepsis can progress to septic shock, which may
requires volume loading and vasopressors in order to
maintain organ function. However, after the publication of
the paradoxical results of the fluid expansion as supportive
treatment (FEAST) trial comparing repeated boluses of 20
mL/kg of either saline or 5% albumin with no bolus in
3141 African children with severe infection,[80] there is
now a trend to restrict unnecessary volume loading in
order to stabilize hemodynamics while preventing the
occurrence of brain and lung edema, especially in resource-
limited settings.[81]
For years, intravenous immunoglobulins (IVIG) have been
used in severe neonatal sepsis, because newborns are
relatively deficient in endogenous immunoglobulins.
However, a large phase III clinical trial of 3493 infants
at 113 hospitals comparing two iv infusions of 500 mg
(10mL) per kg body weight 48 h apart with placebo failed
to demonstrate a significant difference in the incidence of
subsequent sepsis episodes and the rates of major or non-
major disability at 2 years of follow-up.[82] Since the large
clinical trial included neonates from both developing and
developed countries, the negative results should be
interpreted as high-level evidence to abandon IVIG
administration among septic neonates in China.
Conclusions
To sum up, the epidemiology and pathogen profile of
neonatal sepsis may differ substantially between countries
and regions, and data from elsewhere should always
be interpreted with caution before being extrapolated to
any local institution in China. The alarmingly high
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antimicrobial resistance rate of pathogens causing neona-
tal sepsis in China poses a substantial challenge, given its
very large annual birth population.[83] Emphasis is laid on
continuous monitoring of a priori antibiotic susceptibility
of the causative micro-organisms. Notably, viral infection
maymimic clinical signs of bacterial sepsis but require anti-
viral therapy (or no therapy) instead of antibiotics. There is
an urgent need for the early diagnosis of neonatal sepsis
followed by adequate and appropriate empirical therapy.
Equally important is the early cessation of antimicrobial
treatment as soon as negative microbial evidence has been
yielded, despite the presence of isolated abnormal
inflammatory markers. Last but not the least, efficient
communication with both obstetricians for reliable
maternal history and microbiologists for culture results
is strongly recommended, especially in resource-limited
settings in China, to optimize the regimen and duration of
antibiotic treatment.
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